The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 20 January 2009, www.theannals.com, DOI 10.1345/aph.1L492.
 The Annals of Pharmacotherapy: Vol. 43, No. 2, pp. 356-359. DOI 10.1345/aph.1L492
© 2009 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Borja-Hart, N. L
Right arrow Articles by Christensen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borja-Hart, N. L
Right arrow Articles by Christensen, C.

Human Papillomavirus Vaccine Safety in Pediatric Patients: An Evaluation of the Vaccine Adverse Event Reporting System

Nancy L Borja-Hart, PharmD

Assistant Professor, College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, FL

Sandra Benavides, PharmD

Assistant Professor, College of Pharmacy, Nova Southeastern University

Crystal Christensen

PharmD Student, College of Pharmacy, Nova Southeastern University

Reprints: Dr. Borja-Hart, College of Pharmacy, Nova Southeastern University, 3200 S. University Dr., Ft. Lauderdale, FL 33328, nborja{at}nova.edu

Recent news reports have linked the human papillomavirus (HPV) vaccine to serious adverse events (AEs) in children and adolescents. We used the Vaccine Adverse Event Reporting System (VAERS) database to extract postmarketing AEs reported in patients who received the vaccine. Since approval of the HPV vaccine in the US, 3174 AEs occurring in children and adolescents (aged 6–17 y) have been reported to the VAERS. Of these, 191 (6%) were deemed to be serious. Although these AEs are of significant concern, more research is required before they can be directly correlated with the vaccine.

Key Words: Gardasil, human papillomavirus, pediatrics, VAERS

Published Online, January 20, 2009. www.theannals.com, DOI 10.1345/aph.1L492




homecopy help contact us subscription past issues search current issue
Copyright © 2009 by Harvey Whitney Books Company.